Tempus AI (NASDAQ:TEM) CAO Ryan Bartolucci Sells 6,175 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan Bartolucci sold 6,175 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total value of $306,341.75. Following the sale, the chief accounting officer directly owned 67,866 shares in the company, valued at $3,366,832.26. The trade was a 8.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Stock Up 8.8%

NASDAQ:TEM opened at $66.65 on Friday. The stock has a market cap of $12.03 billion, a price-to-earnings ratio of -46.28 and a beta of 3.58. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The stock has a 50-day moving average price of $52.44 and a two-hundred day moving average price of $51.21. Tempus AI, Inc. has a 1 year low of $40.77 and a 1 year high of $104.32.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. During the same period in the previous year, the firm earned ($0.22) EPS. Tempus AI’s quarterly revenue was up 21.6% compared to the same quarter last year. As a group, equities analysts expect that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and reaffirmed a “Buy” rating. The new target implies approximately 20% upside from the referenced price and provides a direct catalyst for buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investors are increasingly focused on Tempus AI’s approximately $1.5 billion all-stock acquisition of Personalis. Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Reported progress involving Moderna and Merck in cancer vaccines has improved sentiment toward genomic-data providers and made Tempus’ Personalis strategy appear more timely. The benefit to TEM is indirect, but the developments support the company’s oncology growth narrative. Tempus AI and cancer vaccine developments
• Positive Sentiment: Call-option volume reached 40,671 contracts, about 57% above typical activity, signaling bullish speculation and potentially amplifying momentum.
• Neutral Sentiment: TEM’s move above key moving averages has been described as a possible short squeeze. This can support further gains, but it also raises volatility and reversal risk. Tempus AI technical rally
• Negative Sentiment: Several executives sold shares, including CEO Eric Lefkofsky, CFO James William Rogers and EVP Andrew Polovin. The sales totaled substantial amounts and reduced their holdings, which can concern investors. However, the transactions were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Piper Sandler dropped their price target on Tempus AI from $58.00 to $56.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 4th. TD Cowen restated a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Wolfe Research began coverage on Tempus AI in a research report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Finally, HC Wainwright decreased their price objective on Tempus AI from $64.00 to $56.00 and set a “buy” rating for the company in a report on Monday, August 3rd. Nine research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Tempus AI currently has an average rating of “Hold” and a consensus price target of $65.69.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in TEM. Royal Bank of Canada increased its stake in Tempus AI by 201.2% in the 1st quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock valued at $1,253,000 after buying an additional 17,359 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of Tempus AI during the 1st quarter worth about $116,000. Prudential Financial Inc. acquired a new position in shares of Tempus AI during the 2nd quarter worth about $276,000. Russell Investments Group Ltd. grew its holdings in shares of Tempus AI by 21.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock valued at $415,000 after acquiring an additional 1,146 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of Tempus AI by 2,926.6% in the second quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock valued at $13,446,000 after acquiring an additional 204,629 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.